Compare Stocks: ASND, RVMD, ALNY, and BIIB

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALNY Alnylam Pharmaceuticals	$222.07 -3.9%	$242.42	$197.81 ▼ $495.55	$29.67B	0.28	1.45 million shs	849,635 shs
ASND Ascendis Pharma A/S	$227.69 +0.2%	$249.55	$186.05 ▼ $282.15	$14.24B	0.38	698,616 shs	378,389 shs
BIIB Biogen	$220.62 -1.0%	$215.32	$138.00 ▼ $230.49	$32.55B	0.09	1.20 million shs	406,933 shs
RVMD Revolution Medicines	$205.80 0.0%	$202.46	$45.72 ▼ $224.31	$44.05B	1.4	2.88 million shs	801,359 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALNY Alnylam Pharmaceuticals	-6.31%	-7.38%	-6.07%	-26.09%	-49.81%
ASND Ascendis Pharma A/S	-0.23%	-1.47%	-12.66%	-17.19%	+11.37%
BIIB Biogen	-1.35%	-1.56%	+3.14%	+3.10%	+44.48%
RVMD Revolution Medicines	+0.31%	+3.02%	-1.90%	+8.80%	+348.95%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALNY Alnylam Pharmaceuticals	$222.07 -3.9%	$242.42	$197.81 ▼ $495.55	$29.67B	0.28	1.45 million shs	849,635 shs
ASND Ascendis Pharma A/S	$227.69 +0.2%	$249.55	$186.05 ▼ $282.15	$14.24B	0.38	698,616 shs	378,389 shs
BIIB Biogen	$220.62 -1.0%	$215.32	$138.00 ▼ $230.49	$32.55B	0.09	1.20 million shs	406,933 shs
RVMD Revolution Medicines	$205.80 0.0%	$202.46	$45.72 ▼ $224.31	$44.05B	1.4	2.88 million shs	801,359 shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALNY Alnylam Pharmaceuticals	-6.31%	-7.38%	-6.07%	-26.09%	-49.81%
ASND Ascendis Pharma A/S	-0.23%	-1.47%	-12.66%	-17.19%	+11.37%
BIIB Biogen	-1.35%	-1.56%	+3.14%	+3.10%	+44.48%
RVMD Revolution Medicines	+0.31%	+3.02%	-1.90%	+8.80%	+348.95%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALNY Alnylam Pharmaceuticals	2.83	Moderate Buy	$366.90	65.22% Upside
ASND Ascendis Pharma A/S	3.00	Buy	$310.75	36.48% Upside
BIIB Biogen	2.56	Moderate Buy	$230.14	4.32% Upside
RVMD Revolution Medicines	2.96	Moderate Buy	$234.33	13.86% Upside

Current Analyst Ratings Breakdown

Latest ASND, RVMD, ALNY, and BIIB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/30/2026	ALNY Alnylam Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
9/30/2026	ALNY Alnylam Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$375.00 ➝ $369.00
9/28/2026	RVMD Revolution Medicines	Brookline Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$318.00
9/25/2026	ASND Ascendis Pharma A/S	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$300.00
9/24/2026	BIIB Biogen	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C-) ➝ Hold (C)
9/24/2026	RVMD Revolution Medicines	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$267.00
9/24/2026	RVMD Revolution Medicines	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$267.00
9/21/2026	ALNY Alnylam Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$455.00
9/21/2026	RVMD Revolution Medicines	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$225.00 ➝ $265.00
9/16/2026	ASND Ascendis Pharma A/S	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$344.00
9/15/2026	ASND Ascendis Pharma A/S	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Outperform	$287.00

(Data available from 10/2/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALNY Alnylam Pharmaceuticals	$3.71B	8.00	$2.52 per share	88.24	$5.97 per share	37.20
ASND Ascendis Pharma A/S	$814.57M	17.44	N/A	N/A	($2.97) per share	-76.66
BIIB Biogen	$9.89B	3.30	$22.11 per share	9.98	$124.45 per share	1.77
RVMD Revolution Medicines	$11.58M	3,809.33	N/A	N/A	$8.44 per share	24.38

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALNY Alnylam Pharmaceuticals	$313.75M	$5.38	41.22	22.89	N/A	15.26%	84.93%	14.30%	10/29/2026 (Estimated)
ASND Ascendis Pharma A/S	-$258M	$12.89	17.72	25.50	N/A	70.99%	32.54%	7.71%	11/11/2026 (Estimated)
BIIB Biogen	$1.29B	$5.65	38.99	13.69	2.49	8.32%	11.18%	6.88%	10/28/2026 (Estimated)
RVMD Revolution Medicines	-$1.13B	-$8.82	N/A	N/A	N/A	N/A	-88.20%	-57.85%	11/4/2026 (Estimated)

Latest ASND, RVMD, ALNY, and BIIB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
10/29/2026	Q3 2026	ALNY Alnylam Pharmaceuticals	$1.77	N/A	N/A	N/A	$1.43 billion	N/A
10/28/2026	Q3 2026	BIIB Biogen	$2.03	N/A	N/A	N/A	$2.64 billion	N/A
8/14/2026	Q2 2026	ASND Ascendis Pharma A/S	$1.71	$1.0270	-$0.6830	$3.23	$376.75 million	$387.22 million
8/5/2026	Q2 2026	RVMD Revolution Medicines	-$2.04	-$3.06	-$1.02	-$3.06	$1.77 million	N/A
7/30/2026	Q2 2026	ALNY Alnylam Pharmaceuticals	$1.63	$1.84	+$0.21	$1.21	$1.32 billion	$1.29 billion
7/29/2026	Q2 2026	BIIB Biogen	$2.94	$3.60	+$0.66	$0.66	$2.46 billion	$2.74 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALNY Alnylam Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ASND Ascendis Pharma A/S	N/A	N/A	N/A	N/A	N/A
BIIB Biogen	N/A	N/A	N/A	N/A	N/A
RVMD Revolution Medicines	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALNY Alnylam Pharmaceuticals	0.75	3.05	2.99
ASND Ascendis Pharma A/S	0.27	2.99	2.32
BIIB Biogen	0.39	1.87	1.26
RVMD Revolution Medicines	0.40	11.38	11.38

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALNY Alnylam Pharmaceuticals	92.97%
ASND Ascendis Pharma A/S	N/A
BIIB Biogen	87.93%
RVMD Revolution Medicines	94.34%

Insider Ownership

Company	Insider Ownership
ALNY Alnylam Pharmaceuticals	0.86%
ASND Ascendis Pharma A/S	40.00%
BIIB Biogen	0.25%
RVMD Revolution Medicines	7.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALNY Alnylam Pharmaceuticals	2,770	133.81 million	132.66 million	Optionable
ASND Ascendis Pharma A/S	1,189	62.38 million	37.43 million	Optionable
BIIB Biogen	7,500	147.75 million	147.39 million	Optionable
RVMD Revolution Medicines	883	214.34 million	198.05 million	Optionable

ASND, RVMD, ALNY, and BIIB Headlines

Recent News About These Companies

Equities Analysts Set Expectations for RVMD FY2027 Earnings

October 2 at 1:28 AM | americanbankingnews.com

Revolution Medicines (NASDAQ:RVMD) Insider Alan Sandler Sells 6,309 Shares of Stock

October 1 at 7:07 PM | marketbeat.com

Analysts Issue Forecasts for RVMD FY2027 Earnings

September 30 at 7:56 AM | marketbeat.com

Revolution Medicines (NASDAQ:RVMD) Stock Picked Up by Analysts at Brookline Capital Markets

September 28, 2026 | marketbeat.com

Bernstein Sticks to Their Hold Rating for Revolution Medicines (RVMD)

September 27, 2026 | theglobeandmail.com

Insider Selling: Revolution Medicines (NASDAQ:RVMD) Director Sells $1,958,004.72 in Stock

September 27, 2026 | americanbankingnews.com

Revolution Medicines (NASDAQ:RVMD) Research Coverage Started at The Goldman Sachs Group

September 27, 2026 | americanbankingnews.com

Revolution Medicines (NASDAQ:RVMD) Shares Climb 4.4% Following Analyst Upgrade

September 27, 2026 | americanbankingnews.com

Revolution Medicines (RVMD) Gets a Buy from Goldman Sachs

September 25, 2026 | theglobeandmail.com

Revolution Medicines (NASDAQ:RVMD) Shares Climb 4.4% on Analyst Upgrade

September 25, 2026 | marketbeat.com

Revolution Medicines (NASDAQ:RVMD) Raised to Strong-Buy at The Goldman Sachs Group

September 25, 2026 | marketbeat.com

Revolution Medicines Receives FDA Breakthrough Designation, Royalty Pharma Offers a Diversified Investment Path

September 25, 2026 | nai500.comN

Revolution Medicines (NASDAQ:RVMD) Stock: Insider Elizabeth Anderson Sells 10,143 Shares

September 24, 2026 | marketbeat.com

Andra AP fonden Has $5.28 Million Stock Holdings in Revolution Medicines, Inc. $RVMD

September 24, 2026 | marketbeat.com

Is Revolution Medicines (RVMD) Cheap After Its FDA Breakthrough Therapy Win?

September 23, 2026 | finance.yahoo.com

Revolution Medicines (NASDAQ:RVMD) Stock Price Expected to Rise, Bank of America Analyst Says

September 23, 2026 | americanbankingnews.com

Revolution Medicines (RVMD) Wins FDA Breakthrough Status For RASONQUE

September 22, 2026 | finance.yahoo.com

Revolution Medicines (RVMD) Deepens RAS(ON) Bet With Breakthrough PDAC Combo – But Is Risk Repricing?

September 22, 2026 | finance.yahoo.com

44,928 Shares in Revolution Medicines, Inc. $RVMD Acquired by Nykredit A S

September 22, 2026 | marketbeat.com

Bank of America Forecasts Strong Price Appreciation for Revolution Medicines (NASDAQ:RVMD) Stock

September 21, 2026 | marketbeat.com

Insider Selling: Revolution Medicines (NASDAQ:RVMD) Insider Sells $67,940.84 in Stock

September 21, 2026 | americanbankingnews.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ASND, RVMD, ALNY, and BIIB Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

$222.07 -9.11 (-3.94%)

As of 02:32 PM Eastern

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Ascendis Pharma A/S NASDAQ:ASND

$227.68 +0.38 (+0.16%)

As of 02:31 PM Eastern

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Biogen NASDAQ:BIIB

$220.62 -2.21 (-0.99%)

As of 02:31 PM Eastern

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Revolution Medicines NASDAQ:RVMD

$205.80 -0.09 (-0.04%)

As of 02:32 PM Eastern

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ASND, RVMD, ALNY, and BIIB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ASND, RVMD, ALNY, and BIIB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ASND, RVMD, ALNY, and BIIB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ASND, RVMD, ALNY, and BIIB Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

Ascendis Pharma A/S NASDAQ:ASND

Biogen NASDAQ:BIIB

Revolution Medicines NASDAQ:RVMD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ASND, RVMD, ALNY, and BIIB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ASND, RVMD, ALNY, and BIIB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ASND, RVMD, ALNY, and BIIB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ASND, RVMD, ALNY, and BIIB Company Descriptions

Alnylam Pharmaceuticals NASDAQ:ALNY

Ascendis Pharma A/S NASDAQ:ASND

Biogen NASDAQ:BIIB

Revolution Medicines NASDAQ:RVMD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools